CanSino’s Ad5-nCoV for emergency use as a booster dose, China has become the first country to approve a needle-free, inhaled version of a Covid-19 vaccine, said an official statement quoted by news agency Bloomberg.
The inhaled Covid-19 vaccine, made by Tianjin-based CanSino Biologics Inc, has pushed the company's shares up by 14.5% on Monday morning in Hong Kong, the organization said in a statement to the Hong Kong Stock Exchange yesterday.
The vaccine, which had undergone human testing in March 2020, is a new version of CanSino's one-shot Covid drug. It has been used in China, Mexico, Pakistan, Malaysia, and Hungary after being rolled out in February 2021.
1) An early-stage clinical trial showed that the inhaled-version of CanSino BioLogics' (CanSinoBIO) COVID-19 vaccine triggered immune responses without serious side effects.